Jagged-1 and Notch3 Juxtacrine Loop Regulates Ovarian Tumor Growth and Adhesion

Overview

Journal Cancer Res

Specialty Oncology

Date 2008 Jul 18

PMID 18632624

Citations 72

Authors

Jung-Hye Choi

Joon T Park

Ben Davidson

Patrice J Morin

Ie-Ming Shih

Tian-Li Wang

Affiliations

Soon will be listed here.

Abstract

Notch3 gene amplification and pathway activation have been reported in ovarian serous carcinoma. However, the primary Notch3 ligand that initiates signal transduction in ovarian cancer remains unclear. In this report, we identify Jagged-1 as the highest expressed Notch ligand in ovarian tumor cells as well as in peritoneal mesothelial cells that are in direct contact with disseminated ovarian cancer cells. Cell-cell adhesion and cellular proliferation were reduced in Notch3-expressing ovarian cancer cells that were cocultured with Jagged-1 knockdown mesothelial and tumor feeder cells. Interaction of Notch3-expressing ovarian cancer cells with Jagged-1-expressing feeder cells activated the promoter activity of candidate Notch3 target genes, and this activity was attenuated by Notch3 siRNA. Constitutive expression of the Notch3 intracellular domain significantly suppressed the Jagged-1 shRNA-mediated growth inhibitory effect. In Notch3-expressing ovarian cancer cells, Jagged-1-stimulating peptides enhanced cellular proliferation, which was suppressed by gamma-secretase inhibitor and Notch3 siRNA. Taken together, our results show that Jagged-1 is the primary Notch3 ligand in ovarian carcinoma and Jagged-1/Notch3 interaction constitutes a juxtacrine loop promoting proliferation and dissemination of ovarian cancer cells within the intraperitoneal cavity.

Citing Articles

Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells.

Islam S, Al-Mohanna F, Yousef I, Al-Badawi I, Aboussekhra A Cell Death Dis. 2024; 15(4):247.

PMID: 38575576 PMC: 10995149. DOI: 10.1038/s41419-024-06512-0.

Jagged1 intracellular domain/SMAD3 complex transcriptionally regulates TWIST1 to drive glioma invasion.

Kim J, Hong N, Park S, Ham S, Kim E, Kim S Cell Death Dis. 2023; 14(12):822.

PMID: 38092725 PMC: 10719344. DOI: 10.1038/s41419-023-06356-0.

Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer.

Price Z, Lokman N, Sugiyama M, Koya Y, Yoshihara M, Oehler M Cell Mol Life Sci. 2023; 80(11):320.

PMID: 37815603 PMC: 10564841. DOI: 10.1007/s00018-023-04972-9.

A Novel Notch-Related Gene Signature for Prognosis and Immune Response Prediction in Ovarian Cancer.

Pi Y, Sun F, Zhang Z, Liu X, Lou G Medicina (Kaunas). 2023; 59(7).

PMID: 37512088 PMC: 10385113. DOI: 10.3390/medicina59071277.

Prognostic evaluation of pancreatic cancer based on the model of chemo-radiotherapy resistance-related genes.

Sun H, Zhang W, Chu Y, Zhou L, Gong F, Li W J Gastrointest Oncol. 2023; 14(3):1525-1545.

PMID: 37435207 PMC: 10331760. DOI: 10.21037/jgo-23-308.

References

Ascano J, Beverly L, Capobianco A . The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J Biol Chem. 2002; 278(10):8771-9. DOI: 10.1074/jbc.M211427200. View

Tan D, Agarwal R, Kaye S . Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006; 7(11):925-34. DOI: 10.1016/S1470-2045(06)70939-1. View

Nitta M, Katabuchi H, Ohtake H, Tashiro H, Yamaizumi M, Okamura H . Characterization and tumorigenicity of human ovarian surface epithelial cells immortalized by SV40 large T antigen. Gynecol Oncol. 2001; 81(1):10-7. DOI: 10.1006/gyno.2000.6084. View

Dang L, Yoon K, Wang M, Gaiano N . Notch3 signaling promotes radial glial/progenitor character in the mammalian telencephalon. Dev Neurosci. 2006; 28(1-2):58-69. DOI: 10.1159/000090753. View

Nakayama K, Nakayama N, Kurman R, Cope L, Pohl G, Samuels Y . Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther. 2006; 5(7):779-85. DOI: 10.4161/cbt.5.7.2751. View

Ohtsuka T, Ishibashi M, Gradwohl G, Nakanishi S, Guillemot F, Kageyama R . Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. EMBO J. 1999; 18(8):2196-207. PMC: 1171303. DOI: 10.1093/emboj/18.8.2196. View

Shimizu K, Chiba S, Hosoya N, Kumano K, Saito T, Kurokawa M . Binding of Delta1, Jagged1, and Jagged2 to Notch2 rapidly induces cleavage, nuclear translocation, and hyperphosphorylation of Notch2. Mol Cell Biol. 2000; 20(18):6913-22. PMC: 88767. DOI: 10.1128/MCB.20.18.6913-6922.2000. View

LaVoie M, Selkoe D . The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem. 2003; 278(36):34427-37. DOI: 10.1074/jbc.M302659200. View

Kohler M, Marks J, Wiseman R, Jacobs I, Davidoff A, Clarke-Pearson D . Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst. 1993; 85(18):1513-9. DOI: 10.1093/jnci/85.18.1513. View

10.

Park J, Li M, Nakayama K, Mao T, Davidson B, Zhang Z . Notch3 gene amplification in ovarian cancer. Cancer Res. 2006; 66(12):6312-8. DOI: 10.1158/0008-5472.CAN-05-3610. View

11.

Shih I, Wang T . Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 2007; 67(5):1879-82. DOI: 10.1158/0008-5472.CAN-06-3958. View

12.

Lindsell C, Shawber C, Boulter J, Weinmaster G . Jagged: a mammalian ligand that activates Notch1. Cell. 1995; 80(6):909-17. DOI: 10.1016/0092-8674(95)90294-5. View

13.

Bland C, Kimberly P, Rand M . Notch-induced proteolysis and nuclear localization of the Delta ligand. J Biol Chem. 2003; 278(16):13607-10. DOI: 10.1074/jbc.C300016200. View

14.

Purow B, Haque R, Noel M, Su Q, Burdick M, Lee J . Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005; 65(6):2353-63. DOI: 10.1158/0008-5472.CAN-04-1890. View

15.

Weng A, Aster J . Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev. 2004; 14(1):48-54. DOI: 10.1016/j.gde.2003.11.004. View

16.

Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman R, Shih I . Amplicon profiles in ovarian serous carcinomas. Int J Cancer. 2007; 120(12):2613-7. DOI: 10.1002/ijc.22609. View

17.

Buckhaults P, Zhang Z, Chen Y, Wang T, St Croix B, Saha S . Identifying tumor origin using a gene expression-based classification map. Cancer Res. 2003; 63(14):4144-9. View